Table 2 Correlations between TILS (continuous) and clinical pathological characteristics

From: Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment

 

All cohort (n = 110)

Cohort TILs on metastatic site (n = 57)

Parameters

TILs median (IQR)

p-valuea

TILs median (IQR)

p-valuea

Menopausal status

 Premenopausal

10 (5–15)

0.323

10 (5–15)

0.090

 Postmenopausal

10 (5–20)

10 (5–20)

Stage at diagnosis

 M0

10 (5–15)

0.472

10 (5–15)

0.368

 M1

10 (5–20)

12.5 (5–20)

Neoadjuvant chemotherapy

 No

10 (5–20)

0.306

10 (5–17.5)

0.534

 Yes

10 (5–15)

10 (5–15)

ER status

 Negative

10 (6.3–15)

0.083

10 (5–15)

0.788

 Positive

10 (5–15)

10 (5–20)

PR status

 Negative

10 (5–15)

0.279

10 (5–15)

0.836

 Positive

10 (4–15)

10 (2.5–20)

HR statusb

 Negative

10 (6–15)

0.080

10 (5–15)

0.788

 Positive

10 (5–15)

10 (5–20)

HER2 status

 2+

10 (5–15)

0.889

10 (5–17.5)

0.151

 3+

10 (5–15)

10 (5–15)

Visceral disease

 Yes

10 (5–15)

0.048

10 (5–11.3)

0.428

 No

15 (5–20)

15 (5–15)

Brain disease

 Yes

15 (10–15)

0.383

5 (3.5–10)

0.444

 No

10 (5–15)

10 (5–15)

Site of TILs evaluation

Metastatic site

10 (5–15)

0.590

Liver

5 (5–10)

0.0313

Lung

15 (10–30)

Lymph node

12.5 (2.8–18.8)

Soft Tissue

10 (5.0–16.3)

Bone

7.5 (3.8–11.3)

Primary BC

10 (5–15)

//

Best response

 Complete response

12.5 (8.8–15)

0.554

10 (7.5–15)

0.148

 Partial response

10 (5–15)

7.5 (5–15)

 Stable disease

10 (5–20)

10 (5–20)

 Progression disease

10 (10–15)

2 (2–2)

Alive status

 Alive

10 (5–15)

0.088

10 (5–15)

0.010

 Dead

5 (5–15)

5 (2.8–10)

  1. On the left the whole cohort and on the right the cohort of patients whose TILs were evaluated at the metastatic site.
  2. BC breast cancer, ER estrogen receptor, HR hormone receptor, IQR interquartile range, PR progesterone receptor, TILs tumor-infiltrating lymphocytes.
  3. ap-values are referred to Mann–Whitney test or Kruskall–Wallis test depending on the number of clinical pathological characteristics’ categories (two or more than two, respectively).
  4. bHR: HR+ i.e. ER or PR positive.